conjugated secondary antibodies for 1 hour, and subsequently counterstained with DAPI for 5 minutes at room temperature (Roche Diagnostics). All images were visualized under Carl Zeiss LSM700 fluorescence microscope (ZEISS, Germany) and analyzed using ZEN 2010 software.
Western blotting
Quantified protein lysates were resolved on SDS-PAGE, transferred onto a polyvinylidenedifluoride (PVDF) membrane (Millipore), and then blocked with 5% non-fat milk in Tris-buffered saline-Tween 20 (TBS-T) for 1 hour at room temperature. The blocked membrane was then incubated with primary antibody at 4°C overnight. After washing with TBS-T, the membrane was incubated for 1 hour with horseradish peroxidase (HRP)-conjugated secondary antibody. A complex of primary and secondary antibodies labeled proteins were detected by enhanced chemiluminescence (ECL) system (GE Healthcare) and X-ray film (GE Healthcare). β-actin was used as a housekeeping control. Using antibodies listed in Table S7 .
RHCG overexpression and knockdown
The full-length wild-type RHCG cDNA (NM_016321.2) was cloned into the pLenti6 expression vector (Invitrogen) and transfected into EC109 and KYSE180 cells with Lipofectamine 2000 Reagent (Invitrogen). Stable RHCG-expressing clones were selected for 2 weeks with Blasticidin (Sigma-Aldrich). Empty vector (EV)-transfected cells were used as controls. For RHCG knockdown, the scrambled shRNA plasmid (pLKO.1-NTC) and the RHCGspecific shRNA expression vectors (pLKO.1-shRHCG) were purchased from Sigma-Aldrich.
Two constructs against RHCG were used: shRHCG-1 (TRCN0000059853) and shRHCG-3 (TRCN0000059856). The shRNA sequences listed in Table S8 . The pLKO.1-shRHCG or the scrambled shRNA plasmid was transfected into KYSE520, and stable clones were selected using puromycin (Sigma-Aldrich).
